Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives $13.63 Consensus Target Price from Analysts

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $13.6250.

A number of analysts have recently weighed in on VNDA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, January 21st. B. Riley lifted their price objective on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, December 31st. Wall Street Zen raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Jefferies Financial Group raised their target price on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a report on Wednesday, December 31st. Finally, HC Wainwright lifted their price target on shares of Vanda Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, January 5th.

Vanda Pharmaceuticals Stock Up 3.1%

NASDAQ VNDA opened at $8.02 on Friday. The business’s fifty day simple moving average is $6.76 and its 200-day simple moving average is $5.46. The company has a quick ratio of 3.10, a current ratio of 3.12 and a debt-to-equity ratio of 0.01. The firm has a market cap of $473.98 million, a PE ratio of -5.65 and a beta of 0.60. Vanda Pharmaceuticals has a 52 week low of $3.81 and a 52 week high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). The business had revenue of $56.26 million during the quarter, compared to analyst estimates of $58.73 million. Vanda Pharmaceuticals had a negative net margin of 39.70% and a negative return on equity of 16.82%. As a group, equities analysts anticipate that Vanda Pharmaceuticals will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at approximately $95,000. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Vanda Pharmaceuticals by 33.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 23,413 shares of the biopharmaceutical company’s stock worth $190,000 after purchasing an additional 5,913 shares during the period. JPMorgan Chase & Co. grew its position in Vanda Pharmaceuticals by 16.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 199,893 shares of the biopharmaceutical company’s stock valued at $997,000 after buying an additional 28,238 shares during the last quarter. Krensavage Asset Management LLC increased its stake in Vanda Pharmaceuticals by 15.2% in the 3rd quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock valued at $5,890,000 after buying an additional 155,505 shares during the period. Finally, PharVision Advisers LLC purchased a new position in Vanda Pharmaceuticals during the 3rd quarter worth $285,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.